Foot mycosis: how to help active patients
https://doi.org/10.21518/2079-701X-2020-12-24-27
Abstract
Mycotic infections of the feet are common fungal infections in our time. According to some reports, about 10% of the world's population suffer from these infections. Men suffer from foot mycosis more often than others. Foot mycosis can manifest itself in three clinical forms: interdigital, plantar and vesiculopapular. Foot mycosis is often combined with onychomycosis or becomes a risk factor for its development. Many diseases, such as diabetes mellitus, vascular diseases, obesity are risk factors for foot mycosis. But what is important is that young and middle-aged people who lead an active lifestyle are at risk. It has long been established that public places such as gyms, swimming pools, baths and saunas are a source of mycotic infections. The internal climatic environment of footwear also has a significant impact on the development of foot mycosis. Closed shoes with high internal temperature and humidity create ideal conditions for dermatophyte growth. That is why people who prefer closed, even cloth shoes, or office workers, who are forced to constantly wear closed shoes, often suffer from foot mycosis and other fungal infections.
The main problem in the treatment of foot mycoses is adherence to the prescribed treatment. In our practice, mycotic lesions are more common in people who lead an active lifestyle and are unable to adhere to a long course of therapy. Indeed, the treatment of mycosis often involves a two-week application of some topical antifungal agent. It is optimal to prescribe a single application of terbinafine film forming solution to such patients. This drug ensures the clinical effectiveness of therapy as it keeps antifungi-cidal activity for 13 days from the date of application and high adherence to treatment.
About the Authors
L. R. Sakaniya
Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences; Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology
Russian Federation
Russian Federation
Luiza R. Sakaniya - Junior Researcher, Center for Theoretical Problems of Physicochemical Pharmacology RAS; Dermatovenerologist, Moscow Scientific and Practical Center for Dermatology and Cosmetology of the Moscow Healthcare Department.
30, Srednyaya Kalitnikovskaya St., Moscow, 109029; 20, Seleznevskaya St., Moscow, 127473.
I. M. Korsunskaya
Center for Theoretical Problems of Physicochemical Pharmacology of the Russian Academy of Sciences
Russian Federation
Russian Federation
Irina M. Korsunskaya - Dr. of Sci. (Med.), Professor, Head of Laboratory, Center for Theoretical Problems of Physicochemical Pharmacology RAS.
30, Srednyaya Kalitnikovskaya St., Moscow, 109029.
References
1. Perea S., Ramos M.J., Garau M., Gonzalez A., Noriega A.R., Del Palacio A. Prevalence and risk factors of Tinea unguium and Tinea pedis in the general population in Spain. J Clin Microbiol. 2000;38(9):3226-3230. doi: 10.1128/JCM.38.9.3226-3230.2000.
2. Mazza M., Refojo N., Davel G., Lima N., Dias N., Passos da Silva C.M.F., Canteros C.E. Epidemiology of dermatophytoses in 31 municipalities of the province of Buenos Aires, Argentina: A 6-year study. Rev Iberoam Micol. 2018;35(2):97-102. doi: 10.1016/j.riam.2017.07.002.
3. Zuber T.J., Baddam K. Superficial fungal infection of the skin: where and how it appears help determine therapy. Postgrad Med. 2001;109(1):117-132. doi: 10.3810/pgm.2001.01.830.
4. Weitzman I., Summerbell R.C. The dermatophytes. Clin Microbiol Rev. 1995;8(2):240-259. Available at: https://www.ncbi.nlm.nih.gov/pmc/arti-cles/PMC172857/.
5. Watanabe S., Harada T., Hiruma M., Iozumi K., Katoh T., Mochizuki T. et al. Epidemiological survey of foot diseases in Japan: results of 30,000 foot checks by dermatologists. J Dermatol. 2010;37(5):397-406. doi: 10.1111/j.1346-8138.2009.00741.x.
6. Sasagawa Y. Internal environment of footwear is a risk factor for tinea pedis. J Dermatol. 2019;46(11):940-946. doi: 10.1111/13468138.15060.
7. Gupta A.K., Konnikov N., MacDonald P., Rich P., Rodger N.W., Edmonds M.W. et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol. 1998;139(4):665-667. doi: 10.1046/j.1365-2133.1998.02464.x.
8. Ogasawara Y. Prevalence and patient's consciousness of tinea pedis and onychomycosis. Nihon Ishinkin Gakkai Zasshi. 2003;44(4):253-260. doi: 10.3314/jjmm.44.253.
9. Lee W.J., Kim S.L., Jang Y.H., Lee S.-J., Kim D.W., Bang Y.J., Jun J.B. Increasing prevalence of Trichophyton rubrum identified through an analysis of 115,846 cases over the last 37 years. J Korean Med Sci. 2015;30(5):639-643. doi: 10.3346/jkms.2015.30.5.639.
10. Rippon J.W. Dermatomycoses. In: Rippon J.W. (ed). Medical Mycology: The Pathogenic Fungi and the Pathogenic Actinomycetes. 3rd ed. Philadelphia, PA: W.B Saunders Co.; 1998, рр. 218-224.
11. Havlickova B., Czaika V.A., Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl. 4):2-15. doi: 10.1111/j.1439-0507.2008.01606.x.
12. Shemer A., Gupta A.K., Amichai B., Baum S., Barzilai A., Farhi R. et al. Increased Risk of Tinea Pedis and Onychomycosis Among Swimming Pool Employees in Netanya Area, Israel. Mycopathologia. 2016;181(11-12):851-856. doi: 10.1007/s11046-016-0040-5.
13. Peres N.T.A., Maranhao F.C.A., Rossi A., Martinez-Rossi N.M. Dermatophytes: host-pathogen interaction and antifungal resistance. An Bras Dermatol. 2010;85(5):657-667. doi: 10.1590/s0365-05962010000500009.
14. Lipner S.R., Scher R.K. Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853-867. doi: 10.1016/j.jaad.2018.05.1260.
15. Ryder N.S. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126(s39):2-7. doi: 10.1111/j.1365-2133.1992.tb00001.x.
Review
For citations:
Sakaniya LR, Korsunskaya IM. Foot mycosis: how to help active patients. Meditsinskiy sovet = Medical Council. 2020;(12):24-27. (In Russ.) https://doi.org/10.21518/2079-701X-2020-12-24-27
Views:
565
Email this article 